Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Technology / HOPE Therapeutics deploys Zeta TMS
Tech medical treatment deployment

HOPE Therapeutics deploys Zeta TMS

Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 25, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The deployment of the Zeta TMS Navigation System by MiNK Therapeutics, a subsidiary of NRx Pharmaceuticals, is expected to positively impact NRx Pharmaceuticals' stock price due to the advancement of its interventional psychiatry platform and potential for improved patient outcomes. This also signals a positive development for Zeta Surgical as its FDA-cleared technology gains wider adoption in the medical field, potentially increasing its market valuation.

biotechnology healthcare medical devices
Event Summary

NRx Pharmaceuticals' subsidiary, MiNK Therapeutics, has begun treating its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, Florida. This marks a transition from research deployment to active patient care, integrating AI-powered, sub-millimetric image guidance into routine outpatient TMS workflows for patients with Major Depressive Disorder and other neurological conditions. The deployment supports NRx Pharmaceuticals' planned clinical trial program of NRX-101 in combination with robotic-enabled TMS for patients with depression and suicidality.

Entities Involved
stock
NRx Pharmaceuticals
NRx Pharmaceuticals, through its subsidiary MiNK Therapeutics, has begun treating patients with the Zeta TMS Navigation System, advancing its interventional psychiatry platform and supporting its planned clinical trials. This enhances its market position in CNS disorder treatments.
Importance 100.0 Sentiment 60.0
stock
MiNK Therapeutics
MiNK Therapeutics, a subsidiary of NRx Pharmaceuticals, has transitioned from system deployment to active patient care using the Zeta TMS Navigation System, offering advanced psychiatric and neurological care.
Importance 90.0 Sentiment 60.0
priv
Zeta Surgical
Zeta Surgical's FDA-cleared Zeta TMS Navigation System is now being used by MiNK Therapeutics for patient treatments, demonstrating the commercial availability and application of its AI-powered image guidance technology.
Importance 80.0 Sentiment 60.0
per
Jonathan Javitt
Jonathan Javitt, as Chairman and CEO of NRx Pharmaceuticals and MiNK Therapeutics, provided a statement on the significance of treating the first patients with the Zeta TMS Navigation System.
Importance 30.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration cleared the Zeta TMS Navigation System, which is a prerequisite for its commercial use in the United States.
Importance 20.0 Sentiment 0.0
cnt
United States
The Zeta Navigation System and Zeta TMS Navigation System are commercially available in the United States, indicating the market where these treatments are being deployed.
Importance 10.0 Sentiment 0.0
Relationships
MiNK Therapeutics related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.